Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc is a clinical-stage biopharmaceutical company developing novel therapies for chronic liver disease and neurodegenerative disorders. The company's news flow primarily focuses on clinical trial updates, regulatory interactions, and scientific presentations related to its two main drug candidates.
The BIV201 program for liver disease generates news around clinical trial progress, regulatory milestone achievements, and patent developments. Updates typically cover trial design discussions with regulatory authorities, patient enrollment progress, and data readouts from ongoing studies evaluating the drug's potential to reduce ascites in cirrhotic patients. Announcements may also address manufacturing developments and formulation optimization efforts.
The bezisterim neurodegenerative disease program produces news related to multiple clinical trials across different indications. Updates frequently include data presentations at major medical conferences, results from completed trial phases, and announcements of new trial initiations. Conference presentations often showcase detailed analyses of cognitive assessments, motor function evaluations, and biomarker data from Alzheimer's and Parkinson's disease studies.
Corporate news includes announcements of strategic partnerships, intellectual property developments, and financing activities that support clinical development programs. The company periodically provides pipeline updates outlining development priorities and timelines for upcoming clinical milestones. Scientific publications in peer-reviewed journals may also generate news coverage when research findings are formally published.
Regulatory news encompasses communications regarding clinical trial design approvals, regulatory designation grants, and interactions with health authorities. These announcements often signal important validation of development approaches and may impact development timelines and regulatory pathways. Patent issuances and intellectual property developments also generate newsworthy announcements that strengthen the company's competitive position.
Investor-focused news includes financial results, corporate presentations, and guidance on upcoming data catalysts. The company participates in healthcare investor conferences and may announce key opinion leader webinars that provide deeper insights into disease areas and drug mechanisms of action.
BioVie Inc. (NASDAQ: BIVI) has announced a webinar on October 26, 2021, addressing neuroinflammation and insulin resistance related to Alzheimer's Disease. Key opinion leaders will discuss the inflammatory mechanisms in Alzheimer's, while BioVie management will outline the clinical progress of NE3107, their treatment candidate targeting Alzheimer's. The NM101 Phase III clinical study for NE3107 has begun, with 316 subjects enrolled for this randomized trial aimed at treating mild to moderate Alzheimer's. This initiative marks a significant step in BioVie’s plans for addressing neurodegenerative disorders.
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. A presentation is scheduled for September 29, 2021, at 11:20 a.m. EST, with a webcast available for investors. BioVie, focused on innovative therapies for neurological and liver diseases, is also progressing its Phase 2 study for its Orphan drug candidate BIV201 and initiating a Phase 3 study for NE3107 in Alzheimer's disease. More details can be found on their website.
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit on September 22, 2021, at 12:25 p.m. EST. This conference will provide an update on BioVie’s innovative drug therapies targeting neurodegenerative disorders and advanced liver disease. BioVie is currently evaluating BIV201 for refractory ascites and plans to initiate a Phase 3 study for hepatorenal syndrome. Additionally, the company is conducting a pivotal study for NE3107, aimed at treating Alzheimer's disease, with results expected in late 2022.
BioVie Inc. (NASDAQ: BIVI) has successfully closed its underwritten public offering, raising $20 million through the sale of 2.5 million shares of Class A common stock at $8.00 each. The offering includes an option for underwriters to purchase an additional 375,000 shares for overallotments. Proceeds will primarily support general corporate purposes. BioVie is advancing drug therapies for neurological disorders, liver diseases, and certain cancers, with notable candidates like BIV201 for liver disease and NE3107 targeting Alzheimer's.
BioVie Inc. (NASDAQ: BIVI) has priced its public offering of 2,500,000 shares of Class A common stock at $8.00 per share, generating gross proceeds of $20,000,000. The underwriters have a 45-day option to purchase an additional 375,000 shares. Proceeds will primarily be used for general corporate purposes. The offering is conducted under a shelf registration statement filed with the SEC. BioVie is developing therapies for neurological disorders and liver disease, including BIV201, which is in clinical trials aimed at addressing significant medical needs.
BioVie Inc. (NASDAQ: BIVI) announced plans for an underwritten public offering of its common stock, with all shares to be sold by the company. The offering is managed by ThinkEquity and is subject to market conditions, with no guarantee on its completion or terms. Proceeds are intended for general corporate purposes. The securities will be offered under a registration statement filed with the SEC. The company is engaged in developing therapies for chronic conditions, including a Phase 2 study of BIV201 for liver disease and a Phase 3 study of NE3107 for Alzheimer's.
BioVie Inc. (NASDAQ: BIVI) has initiated the NM101 Phase III clinical study, enrolling its first patient to test NE3107 for Alzheimer’s Disease. This pivotal study involves 316 subjects and aims to assess cognitive, functional, and behavioral endpoints, as well as brain glucose utilization. NE3107 has shown promise in previous studies for reducing neuroinflammation and insulin resistance, which are associated with cognitive decline in Alzheimer’s. The study's results are expected by the end of 2022.
BioVie is also advancing its liver disease treatment, BIV201, and plans to evaluate NE3107 in Parkinson’s Disease.
BioVie Inc. announced its pivotal Phase 3 trial of NE3107, an anti-inflammatory insulin sensitizer for Alzheimer’s Disease. The trial, named NM101, involves 316 subjects and aims to assess various cognitive and glycemic endpoints. Previous studies showcased NE3107's efficacy in reducing neuroinflammation and insulin resistance, critical to Alzheimer’s pathology. The trial is set to complete data analysis by late 2022. Furthermore, BioVie is developing another drug, BIV201, for liver disease, with results expected in early 2022. NE3107 and related compounds are patented first-in-class molecules.
BioVie to Present Phase 3 Alzheimer's Trial at AAIC
BioVie Inc. announced its participation in the 2021 Alzheimer’s Association International Conference (AAIC) from July 26-30, where it will present its Phase 3 trial NM101 for NE3107, aiming to treat mild to moderate Alzheimer's disease. The trial is a randomized, placebo-controlled study involving 316 subjects, assessing cognitive functions and glycemic control. The trial's primary completion is expected by late 2022, marking a significant advancement in anti-inflammatory therapies for Alzheimer’s.
BioVie Inc. has announced the upcoming pivotal Phase 3 trial of its drug candidate NE3107 for treating Alzheimer’s disease, expected to start in summer 2021. The trial aims to evaluate NE3107's effectiveness in slowing cognitive decline and is based on a published article detailing its scientific rationale. NE3107 has shown a favorable safety profile and potential for neuroinflammation and insulin resistance inhibition. This trial will involve approximately thirty clinical sites in the U.S. and is pivotal in addressing significant unmet medical needs in Alzheimer’s care.
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
